MAKERS LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122 INR | -2.28% |
|
-5.17% | -11.98% |
| 23/05 | Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories | MT |
| 23/05 | Makers Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 1.28B 15.44M | Sales 2023 | 1.01B 12.18M | Capitalization | 576M 6.93M |
|---|---|---|---|---|---|
| Net income 2022 | 49M 589K | Net income 2023 | -47M -565K | EV / Sales 2022 | 0.79 x |
| Net Debt 2022 | 112M 1.35M | Net Debt 2023 | 94.83M 1.14M | EV / Sales 2023 | 0.66 x |
| P/E ratio 2022 |
18
x | P/E ratio 2023 |
-12.4
x | Employees | 121 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.69% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.28% | ||
| 1 week | -5.17% | ||
| Current month | -2.28% | ||
| 1 month | -14.54% | ||
| 3 months | +0.29% | ||
| 6 months | +11.93% | ||
| Current year | -11.98% |
1 week
120.15
135.95
1 month
120.15144.95
Current year
108.40155.00
1 year
98.05157.00
3 years
94.00251.75
5 years
23.20344.80
10 years
16.80344.80
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 01/96/01 | |
Sandeep Kadam
DFI | Director of Finance/CFO | 57 | 26/96/26 |
| Sales & Marketing | 52 | 02/17/02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 76 | 29/09/29 | |
| Chairman | 75 | 13/19/13 | |
| Chief Executive Officer | 49 | 01/96/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 122 | -2.28% | 1 654 |
| 31/24/31 | 124.8 | -2.58% | 1,868 |
| 30/24/30 | 128.2 | -2.77% | 2,773 |
| 29/24/29 | 131.8 | +1.23% | 1,355 |
| 28/24/28 | 130.2 | +1.20% | 4,093 |
Delayed Quote Bombay S.E., June 03, 2024 at 01:26 pm IST
More quotes
Makers Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceuticals. The Company operates through the pharmaceuticals segment. Its product portfolio covers a range of general health therapeutic segments. Its formulation brands are Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range) and Exylin (Amoxycillin range). Its Inspira retail packs division includes acid regulatory (PPIS), anthelmintics, anti-allergic, anti-asthmatic, anti-biotics, anti-diabetics, anti-diarrheal, anti-emetics and anti-nauseants, anti-fungal, anti-hypertensives, and others. Its Experia bulk packs division includes amoxycillin 250 mg capsules, betamethasone 0.5 mg tablets, cetirizine HCL 10 mg tablets, chloramphenicol capsules 250 mg, chloroquine phosphate 250 mg tablets, chlorpheniramine maleate 4 mg tablets, ciprofloxacin hydrochloride 250 mg tablets, and others.
Sector
Pharmaceuticals
Calendar
09/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.98% | 8.83M | |
| +16.17% | 41.97B | |
| +22.56% | 22.34B | |
| +15.82% | 15.25B | |
| +16.32% | 14B | |
| +50.00% | 12.06B | |
| -10.77% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- MAKERSL6 Stock
